Evidence map›Paper›PMID 18265979›Full record

ArticleCancer immunology, immunotherapy : CII2008

Fas-mediated T cell deletion potentiates tumor antigen-specific tolerance in a mouse model of prostate cancer.

Stephanie S Tseng-Rogenski, Mohamed S Arredouani, Yilin C Neeley, Bin Lu, Arul M Chinnaiyan, Martin G Sanda

Open access · greenAbstract read
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Drug discovery in prostate cancer mouse models.Expert opinion on drug discovery · 2015
    Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Stephanie S Tseng-RogenskiDepartments of Urology and Pathology, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, MI 48109, USA.
Mohamed S Arredouani
Yilin C Neeley
Bin Lu
Arul M Chinnaiyan
Martin G Sanda
University of Michigan–Ann Arbor · USHarvard University · USBeth Israel Deaconess Medical Center · US

Funding

University of Michigan O'Brien Center for Urology ResearchP50DK065313 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SANDA, MARTIN G · 2003 to 2007
$3.3M
MODULATING TOLERANCE FOR PROSTATE CANCER ANTIGEN VACCINER01CA082419 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SANDA, MARTIN G · 2000 to 2003
$1.1M
NCI NIH HHS R01 CA082419NCI NIH HHS R01 CA82419NIDDK NIH HHS P50 DK065313
6 · The paper itself

Abstract

A pivotal obstacle to cancer immunotherapy is peripheral T cell tolerance to tumor-associated antigens (TAAs). Tolerance induction among mature T cells in the periphery operates through a variety of mechanisms, including anergy and apoptosis. Although Fas-FasL-mediated apoptosis is a well-defined tolerance inducing mechanism, direct evidence of its interference with TAA-specific immunity in vivo is still lacking. In this report, we used the TRAMP mouse, which expresses SV40 large T antigen (Tag) preferentially in the prostate and develops prostate tumors, as a model system to address the role of Fas-mediated apoptosis in regulating peripheral T cell tolerance. Using RT-PCR and tetramer staining to quantify TAA-specific TCR-expressing cytolytic T lymphocytes (CTLs), we have shown the presence of TAA-specific CTLs at higher levels in TRAMP mice than in syngeneic C57Bl/6 mice. Tag-specific immunization led to the expansion of Tag-specific CTLs in C57Bl/6 mice, and to their elimination in TRAMP mice. Interestingly, in TRAMP mice with deficient Fas (Hybrid TRAMP-lpr/lpr), Tag-specific CTL elimination in response to Tag immunization did not take place. The results of cytolytic-function assays were consistent with induction and elimination patterns of TAA-specific CTLs and those of RT-PCR and tetramer staining. In conclusion, our data show that Fas-mediated TAA-specific CTL apoptosis contributes to T cell tolerance and suggest that such tolerance could be potentiated following TAA-specific immunization.

Indexed as

AdenocarcinomaAnimalsAntigens, NeoplasmAntigens, Polyomavirus TransformingApoptosisCell Line, TumorDisease Models, Animalfas ReceptorMaleMiceMice, Inbred C57BLMice, TransgenicProstatic NeoplasmsT-LymphocytesT-Lymphocytes, CytotoxicAntigens, NeoplasmAntigens, Polyomavirus Transformingfas Receptor

Identifiers

PMID18265979
PMCPMC11030269
OpenAlexW2008017907

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.